Massive Pulmonary Embolism Presenting as Obstructive Shock in a Nigerian Woman: A Case Report

Bernard B Akpu¹, Chidimma A Ahaneku²*, Agbo J Etim¹, Ezoke J Epoke¹, David E Elem¹, Bassey E Ekeng³, Edikan B Bassey⁴, Chibueze H Njoku², Victor O Ansa¹, Clement O Odigwe¹

Abstract

Background: Massive pulmonary embolism is a life-threatening emergency associated with high mortality if prompt diagnosis and urgent intervention is delayed, especially in patients presenting in obstructive shock. It usually requires advanced therapies such as systemic thrombolysis, pharmacomechanical catheter-directed therapy, surgical embolectomy and inferior vena cava filter placement. The dearth in skilled manpower, delay in diagnosis, relative unavailability and high cost of fibrinolytics especially in resource poor environments may account for poor clinical outcomes and eventually death in such patients.

Case Presentation: We present a 50-year-old Nigerian woman of Bahumono ethnicity who was admitted into our hospital with complains of sudden onset breathlessness. On presentation, she was tachypneic, tachycardic and hypotensive. D- Dimer and Troponin I levels were elevated. Computed tomography pulmonary angiography (CTPA) with intravenous contrast confirmed the diagnosis of massive pulmonary embolism. She was initially treated with low molecular weight heparin, then thrombolyzed with intravenous alteplase and later discharged on tablet dabigatran. Her symptoms had resolved at the time of discharge and she has remained stable for over 3 months.

Conclusion: Pulmonary embolism, the most serious clinical presentation of venous thromboembolism can become catastrophic when it presents as the massive type. Prompt diagnosis and urgent appropriate medical intervention ensures good clinical outcomes.

Keywords: Alteplase; Massive Pulmonary Embolism; Obstructive Shock; Troponin I

Abbreviations: AHA: American Heart Association; CT: Computed Tomography; CTPA: Computed Tomography Pulmonary Angiography; DVT: Deep Vein Thrombosis; OC: Degree Centigrade; ESC: European Society of Cardiology; HRCT: High Resolution Computed Tomography; INR: International Normalized Ratio; LV: Left Ventricular; PE: Pulmonary embolism; RV: Right Ventricular; tPA Tissue plasminogen activator

Background

Pulmonary embolism (PE) is an obstructive disease of the pulmonary arterial system caused by the embolization of thrombus originating from outside the lungs especially the deep veins of the lower extremities [1, 2]. The thrombus can also occur de-novo without any evidence of deep vein thrombosis (DVT) [3]. PE is one of the most common cardiovascular diseases,
occurring in 1-2 per 1,000 people annually [2]. Virchow first described the process of thrombosis as a triad of stasis, hypercoagulability, and endothelial injury [1, 3]. Patient with PE may present classically with shortness of breath, pleuritic chest pain, cough, orthopnea, wheezing, hemoptysis or less commonly cardiac arrhythmias, syncopal attack or more devastatingly, circulatory collapse [4] depending on the size, number, site of thrombi/emboli and risk factors present [5].

PE is grouped into prognostic categories by the European Society of Cardiology (ESC) and American Heart Association (AHA) into high-risk (massive), intermediate-risk (sub-massive) and low-risk (non-massive) at frequencies of 20%, 32% and 48% respectively [6]. Massive PE, an uncommon and life-threatening presentation of PE is defined as obstruction of the pulmonary arterial tree that exceeds 50% of the cross-sectional area, causing acute and severe cardiopulmonary failure from right ventricular overload [7]. Shock refers to a circulatory failure those results in inadequate cellular oxygen supply and utilization [8]. According to Cox and Hinshaw [9], shock is classified into cardiogenic, hypovolemic, distributive and obstructive shock based on the cause. The most frequent causes of obstructive shock include PE, pneumothorax and cardiac tamponade [8]. The average mortality rate from PE is 11%, but may be significantly higher in patients in shock (40-50%) [9]. The overall mortality rates for massive, sub-massive and non-massive PE are 71.4%, 44.5% and 28.1% respectively [10]. In patients with massive PE, 50% die within 30 minutes, 70% die within 1 hour, and more than 85% die within 6 hours of the onset of symptoms [11].

Consequently, a high index of suspicion, urgent diagnosis and treatment are of critical importance. Thrombolytic therapy is currently recommended for the treatment of massive PE and Alteplase (tPA) is the most common thrombolytic agent used [12]. Massive PE is rare [13] and to the best of our knowledge, massive PE presenting as obstructive shock has not been reported in Nigeria. We report this case of massive pulmonary embolism presenting as obstructive shock in a 50-year-old Nigerian woman.

Case Presentation

A 50-year old female, obese, newly diagnosed diabetic but not a known hypertensive was admitted into the hospital with a one week history of sudden onset of breathlessness. There was associated history of palpitations but no chest pain, orthopnea, paroxysmal nocturnal dyspnea or leg swelling. She had a past history of left leg DVT about a year prior to presentation. There was no history of tobacco or alcohol use. On examination, she was afebrile with a temperature of 37°C. She was not pale. She was anicteric, acyanotic and had no peripheral edema. She had tachycardia (pulse rate - 135 beats /min) and hypotension (blood pressure- 80/50mmHg). Heart sounds were S4, S1 and S2. She was also tachypneic (respiratory rate- 36 cycles per minute) with SPO2 of 96%. Abdominal and Neurological examinations were not remarkable. Wells score was 6 (likely PE). D dimer was markedly elevated- 11,580ng/ ml (Normal <500ng/ml). Troponin I was also elevated-12.4ng/l (Normal<6ng/l). White blood cell count, platelet count, serum electrolyte urea and creatinine were normal. The findings are presented in Table 1.

Table 1: Laboratory finding.

<table>
<thead>
<tr>
<th>Test</th>
<th>Value</th>
<th>Normal Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin (g/dl)</td>
<td>12.7</td>
<td>11.5-15.5</td>
</tr>
<tr>
<td>White-cell count (per mm3)</td>
<td>9,400</td>
<td>4,000-11,000</td>
</tr>
<tr>
<td>Platelet count (per mm3)</td>
<td>199,000</td>
<td>150000-400000</td>
</tr>
<tr>
<td>Urea (mmol/l)</td>
<td>3.57</td>
<td>2.2- 7.2</td>
</tr>
<tr>
<td>Creatinine (umol/l)</td>
<td>97.24</td>
<td>44.2-106</td>
</tr>
<tr>
<td>Sodium (mmol/l)</td>
<td>141.3</td>
<td>135-145</td>
</tr>
<tr>
<td>Potassium (mmol/l)</td>
<td>3.7</td>
<td>3.5-5.1</td>
</tr>
<tr>
<td>PT(s)</td>
<td>11</td>
<td>11-14</td>
</tr>
<tr>
<td>PTTK(s)</td>
<td>44</td>
<td>20-40</td>
</tr>
<tr>
<td>INR (International Normalized Ratio)</td>
<td>1.3</td>
<td>&lt;1.1</td>
</tr>
<tr>
<td>D-Dimer (ng/mL)</td>
<td>11,580</td>
<td>&lt;500</td>
</tr>
<tr>
<td>Troponin I (ng/l)</td>
<td>12.4</td>
<td>&lt; 6</td>
</tr>
<tr>
<td>FBS (mmol/l)</td>
<td>13.1</td>
<td>3.3 – 5.5</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>8.3</td>
<td>4.0 – 6.0</td>
</tr>
<tr>
<td>Total Cholesterol (mmol/l)</td>
<td>4.5</td>
<td>&lt; 5.2</td>
</tr>
<tr>
<td>HDL-C (mmol/l)</td>
<td>1.04</td>
<td>&gt;1.0</td>
</tr>
<tr>
<td>LDL-C (mmol/l)</td>
<td>2.9</td>
<td>&lt;3.0</td>
</tr>
<tr>
<td>VLDL-C (mmol/l)</td>
<td>21.6</td>
<td>14-24</td>
</tr>
<tr>
<td>Triglyceride (mmol/l)</td>
<td>1.19</td>
<td>&lt;2.0</td>
</tr>
</tbody>
</table>

creatinine were essentially within reference limits (Table 1). Arterial blood gas analysis was not done as facilities were not functional. Electrocardiography showed sinus tachycardia, T wave inversion in anteroseptal leads and Mc Ginne white sign- S1Q3T3 pattern (Figure 1), while echocardiography suggested concentric left ventricular remodeling secondary to hypertensive heart disease, preserved biventricular systolic function, grade 1 left ventricular diastolic impairment and mild pulmonary hypertension (Figure 2). The echocardiographic derived values are as shown in Table 2. Chest X-Ray showed cardiomegaly and aortic unfolding suggestive of hypertensive cardiovascular changes (Figure 3). Doppler Ultrasound of both lower limbs showed no obvious intra luminal thrombus, no loss of compressibility of the deep veins of both lower limbs and no calcifications in the vessel walls (Figure 4).

A diagnosis of massive pulmonary embolism presenting with obstructive shock was made and the patient was...
commenced on anticoagulant therapy with subcutaneous enoxaparin at 1mg/kg 12hrly, inotropic support with dopamine, oxygen therapy, beta blockers (tablet bisoprolol 5mg dly), antidiabetic therapy (insulin and metformin) and artovastatins. However, she remained hypotensive despite inotropic support.

Computed Tomography Pulmonary Angiography (CTPA) was then requested and it showed bilateral pulmonary emboli with more than 75% luminal occlusion of both main bronchial, interlobar and segmental pulmonary arteries confirming the diagnosis of massive PE (Figure 5).

The patient was then commenced on systemic thrombolysis with IV alteplase 100mg over 2 hours. Samples for repeat clotting profile was taken and anticoagulation with SC enoxaparin 100iu 12 hourly was continued for 7 days. Repeat D dimer done after systemic thrombolysis showed a marked reduction from the initial value of 11,580ng/ml to 2,510ng/ml.
ml. Tablet Dabigatran 150mg twice daily was commenced after enoxaparin administration to last for 3 months with a target INR of 1.2 to 1.8.

The patient showed marked clinical improvement and has remained stable since after discharge.

Discussion

Patients with massive PE present with profound dyspnea at rest, often accompanied by anxiety, syncope, or lightheadedness; and medical history may include recent surgery or trauma, congestive heart failure, chronic lung disease, prior venous thromboembolism, or cancer [14]. Thirty percent of patients with PE have no detectable provoking factors [2]. In this index patient, the cardiovascular risk factors were diabetes mellitus, past history of deep vein thrombosis, obesity, sedentary lifestyle, anabolic steroid use and dyslipidemia.

The recently published 2019 ESC guidelines provides a revised definition of high-risk (massive) PE encompassing the following clinical presentations: (i) cardiac arrest; (ii) obstructive shock (defined as systolic blood pressure <90mmHg or vasopressors required to achieve a blood pressure ≥90mmHg despite adequate filling status, in combination with end-organ hypoperfusion); or (iii) persistent hypotension (defined as systolic blood pressure <90mmHg or a systolic pressure drop by ≥40mmHg for longer than 15min, if not caused by new-onset arrhythmia, hypovolemia or sepsis) [15]. Our patient had dyspnea, features of obstructive shock and hypotension confirming the diagnosis of massive (high risk) PE.

Aniteye et al [16] observed that the commonest clinical presentations of the patients admitted with the diagnosis of massive PE were dyspnoea (100.0%) and hypotension (70.3%), which were both present in this index case. Similarly, Ebner et al [15] reported that among their patients classified as having massive (high-risk) PE, 43.0% presented with cardiac arrest, 44.2% with obstructive shock, and 12.8% with persistent hypotension only. Pivetti et al [17] found obstructive shock in 10.2% of their PE cases.

The combination of clinical features and predisposing risk factors has been incorporated into clinical scoring systems that are used to predict the likelihood of PE and determining which investigations to perform [18]. These clinical scoring systems include the Wells score, simplified Geneva score and Pulmonary Embolism Severity Index (PESI). The most extensively validated and widely used is the Wells score where PE is unlikely at values of 0-4 and likely at >4 [6]. Wells score in our patient was 6 (likely PE). The initial diagnostic tests for PE include the D-Dimer assay which is usually elevated in PE. It has good sensitivity, but poor specificity [19]. The D-Dimer level in our patient was 11,580ng/ml (Normal <500ng/ml) and this further heightened our clinical suspicion.

Patients with massive PE present with obstructive shock as abrupt elevation in afterload impairs right ventricular (RV) contractility and causes RV dilatation with bowing of the interventricular septum, impeding left ventricular (LV) diastolic filling and ultimately reducing cardiac output [9, 20]. Worsening tricuspid regurgitation and RV ischemia secondary to RV wall stress and reduced right coronary artery perfusion also exacerbate this process [20]. Biomarkers, including serum troponin I or T may be useful in detecting evidence of this RV dysfunction as their levels increase with subsequent leakage from the RV myocytes into the bloodstream [6]. Troponin I was elevated-12.4ng/l (Normal<6ng/l) in our patient. Computed Tomography Pulmonary Angiography (CTPA)
has over 90% specificity and sensitivity in diagnosing PE in the main, lobar, and segmental pulmonary arteries [21] and will show filling defect, upon contrast enhancement, in these arteries [22]. CTPA was done for our patient whose image showed multiple, large hypo dense filling defects involving both main, interlobar and segmental pulmonary arteries.

Ventilation-Perfusion (V/Q) scanning can be used for diagnosis of PE when CTPA is contraindicated. Echocardiography in PE shows a nonspecific right ventricle (RV) strain pattern, enlarged RV, tricuspid regurgitation and sometimes RV thrombi while electrocardiography shows sinus tachycardia and deep S wave in lead 1, Q wave in lead 3, T wave inversion in lead 3 -S1Q3T3 (these were seen in our patient). Tall P wave (P pulmonale), right bundle branch block, right ventricular hypertrophy and right axis deviation are other features [23]. Chest X-Ray sometimes shows segmental atelectasis, pleural effusion, cardiomegaly, regional oligemia, enlarged pulmonary artery, and parenchymal opacities with unilateral diaphragmatic elevation [23].

Patients with PE are treated according to their hemodynamic status and their risk profile [24]. Thrombolytic therapy is a useful adjunct to heparin in patients who have PE and are hemodynamically unstable [25]. Rapid improvement of RV function and pulmonary perfusion, accomplished with thrombolytic therapy followed by heparin, may lead to a lower rate of death and recurrent PE [25] as the main cause of mortality in massive PE is obstructive shock and associated right ventricular (RV) failure [6]. Alteplase, a tissue plasminogen activator (tPA) is the most common thrombolytic used for the treatment of PE, currently approved by the US Food and Drug Administration (FDA) at a dose of 100mg infused over 2 hours [12] was used for our patient with subsequent resolution of signs and symptoms of PE.

Pivetti et al [17] reported that of the 24 PE patients who suffered obstructive shock, 13 patients given thrombolysis were all alive and showed stable hemodynamic parameters at discharge, whereas 11 patients who were not thrombolysed died during hospital stay. Poor et al [26] reported a case series of two patients in the intensive care unit with massive PE and obstructive shock who had resolution of shock after repeated administration of alteplase.

**Conclusion**

Early recognition, correct diagnosis and treatment of patients with massive PE and obstructive shock using thrombolytic agents is recommended to increase their chances of full recovery and survival. We therefore recommend that practitioners should have a high index of suspicion as mortality is high within minutes to few hours of onset of symptoms of massive PE.

**Declarations**

**Ethics Approval and Consent to Participate**

Not Applicable.

**Consent for Publication**

Written informed consent was obtained from the patient to publish this case report. A copy of the written consent is available for review by the editor of this journal.

**Availability of Data and Materials**

Not applicable.

**Competing Interests**

The authors declare no potential conflicts of interest with respect to the case report, authorship, and/or publication of this article.

**Funding**

The authors received no financial support for the case report.

**Authors’ Contributions**

BBA: Conceptualization, writing-original draft, review and editing, CAA: Conceptualization, literature review, writing-original draft, review and editing, AJE, EJE, DEE, BEE and EBB: Participated in writing, CHN, VOA and COO: Constructive review and editing. All authors have agreed to the final version of this manuscript.

**Acknowledgement**

Not Applicable.

**References**